Indivior’s opioid-treatment study of RBP-6000 meets primary and secondary endpoints
A phase 3 clinical trial of Indivior’s RBP-6000 buprenorphine monthly depot, a new drug for the treatment of opioid use disorder, has met both primary and secondary endpoints versus placebo.
Click on this link for more information.
